Net Cash Provided by (Used in) Financing Activities of iBio, Inc. from 30 Jun 2011 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
iBio, Inc. quarterly and annual Net Cash Provided by (Used in) Financing Activities in USD history and change rate from 30 Jun 2011 to 30 Sep 2025.
  • iBio, Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending 30 Sep 2025 was $46,705,000.
  • iBio, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2025 was $8,929,000, a 64% decline from 2024.
  • iBio, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2024 was $24,494,000, a 964% increase from 2023.
  • iBio, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $2,301,000.
Source SEC data
View on sec.gov
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Change (%)
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Change (%)

iBio, Inc. Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $46,705,000 +$46,867,000 01 Jul 2025 30 Sep 2025 10-Q/A 17 Nov 2025 2026 Q1
Q3 2024 $162,000 -$2,634,000 -107% 01 Jul 2024 30 Sep 2024 10-Q/A 17 Nov 2025 2026 Q1
Q3 2023 $2,472,000 +$1,331,000 +117% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2025 Q1
Q3 2022 $1,141,000 +$1,229,000 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023 2024 Q1
Q3 2021 $88,000 -$36,189,000 -100% 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022 2023 Q1
Q3 2020 $36,101,000 +$36,101,000 01 Jul 2020 30 Sep 2020 10-Q 15 Nov 2021 2022 Q1
Q3 2019 $0 -$1,143,000 -100% 01 Jul 2019 30 Sep 2019 10-Q 16 Nov 2020 2021 Q1
Q3 2018 $1,143,000 +$187,000 +20% 01 Jul 2018 30 Sep 2018 10-Q 14 Nov 2019 2020 Q1
Q3 2017 $956,000 +$997,000 01 Jul 2017 30 Sep 2017 10-Q 13 Nov 2018 2019 Q1
Q3 2016 $41,000 01 Jul 2016 30 Sep 2016 10-Q 09 Nov 2017 2018 Q1

iBio, Inc. Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $8,929,000 -$15,565,000 -64% 01 Jul 2024 30 Jun 2025 10-K 05 Sep 2025 2025 FY
2024 $24,494,000 +$22,193,000 +964% 01 Jul 2023 30 Jun 2024 10-K 05 Sep 2025 2025 FY
2023 $2,301,000 +$8,426,000 01 Jul 2022 30 Jun 2023 10-K/A 24 Sep 2024 2024 FY
2022 $6,125,000 -$84,960,000 -108% 01 Jul 2021 30 Jun 2022 10-K 27 Sep 2023 2023 FY
2021 $78,835,000 +$13,643,000 +21% 01 Jul 2020 30 Jun 2021 10-K 11 Oct 2022 2022 FY
2020 $65,192,000 +$61,739,000 +1788% 01 Jul 2019 30 Jun 2020 10-K 28 Sep 2021 2021 FY
2019 $3,453,000 -$18,953,000 -85% 01 Jul 2018 30 Jun 2019 10-K 13 Oct 2020 2020 FY
2018 $22,406,000 +$22,576,000 01 Jul 2017 30 Jun 2018 10-K 26 Aug 2019 2019 FY
2017 $170,000 01 Jul 2016 30 Jun 2017 10-K 18 Sep 2018 2018 FY
2013 $3,834,000 -$5,202,000 -58% 01 Jul 2012 30 Jun 2013 10-K/A 04 Oct 2013 2013 FY
2012 $9,036,000 +$1,670,356 +23% 01 Jul 2011 30 Jun 2012 10-K/A 04 Oct 2013 2013 FY
2011 $7,365,644 01 Jul 2010 30 Jun 2011 10-K/A 15 Oct 2012 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.